The main objective of this prospective clinical trial is to compare pharmacokinetics and
safety and tolerability of a standard dose (400 mg) with an escalated dose (600 mg; 800 mg)
of moxifloxacin (MFX). This clinical trial will provide important safety information on MFX
in a higher dosage in TB patients.
Phase:
Phase 4
Details
Lead Sponsor:
University Medical Center Groningen
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination